Markets ·
Analysts examine the M&A pipeline for major pharmaceutical companies, assessing deal appetite amid shifting regulatory scrutiny and patent-cliff pressures.
Sell-side analysts are re-examining Big Pharma M&A pipelines as patent cliffs accelerate — AbbVie faces Humira biosimilar attrition, Bristol-Myers risks multi-billion revenue erosion from Eliquis and Revlimid losses, while Pfizer post-COVID carries excess cash against a weakened organic pipeline. Regulatory scrutiny under FTC has eased marginally post-2024 election but remains elevated for mega-deals above $10bn.
Patent cliffs are an existential forcing function: companies with 25-40% revenue at risk over 2025-2030 must acquire or dramatically accelerate internal R&D. Mid-cap biotech targets (oncology, obesity, CNS) trade at premiums anticipating takeout. This dynamic sustains elevated sector M&A multiples.
Acquirers (ABBV, BMY, PFE, MRK) face near-term EPS dilution risk on large deals but longer-term pipeline replenishment. Biotech ETFs (XBI, IBB) remain structurally bid on acquisition optionality. Pure-play mid-caps in GLP-1 adjacencies and oncology (RCUS, MRUS, LEGN) carry highest takeout probability.
Watch FTC posture on pending deals, Q3 earnings calls for explicit BD commentary, and FDA PDUFA dates that crystallise asset valuations as M&A triggers.